Tailored Bacterial Magnetic Nanoparticles For Biomedical Imaging

Project Information

BacToMagicle

Grant agreement ID: 101138879

DOI

10.3030/101138879

Project closed

EC signature date 12 September 2023

Start date 1 November 2023

End date 30 April 2025

Funded under

• European Research Council (ERC)

Total cost

No data

EU contribution

€ 150 000,00

Coordinated by

UNIVERSITAT BAYREUTH
Germany

Periodic Reporting for period 1 - BacToMagicle (Tailored Bacterial Magnetic Nanoparticles For Biomedical Imaging)

Reporting period: 2023-11-01 to 2025-04-30

Summary of the context and overall objectives of the project

Magnetic iron oxide nanoparticles (MNP) hold great promise for biomedical applications such as targeted drug delivery, imaging (magnetic resonance imaging, MRI, and magnetic particle imaging, MPI), and cancer treatment via hyperthermia. Their effectiveness depends on precise physical and chemical properties - especially size, shape, and crystallinity - which influence both magnetic behavior and biological interactions. Different applications require different particle sizes: superparamagnetic particles under 30 nm are ideal for drug delivery, while larger particles (35 - 40 nm) are better for hyperthermia. For magnetic imaging, optimal sizes vary, with MPI requiring highly specific magnetic characteristics in addition to size constraints. Current chemical synthesis methods struggle to produce uniform, biocompatible MNPs with tailored properties, often resulting in inconsistent quality and potential toxicity due to chemical residuals. Thus, in principle, the reliable production of multifunctional, high-performance MNPs has remained an unresolved challenge.
Magnetotactic bacteria (MTB) naturally produce magnetic nanoparticles (magnetosomes) with superior properties - uniform size, high crystallinity and strong magnetization. Unlike chemically synthesized MNPs, magnetosomes possess a genetically encoded blueprint and can be precisely engineered for specific functions. Their biological membrane envelope can be harnessed to anchor a wide spectrum of functional moieties to their surface by genetic means, a substantial advantage for the generation of versatile “theranostic” (both diagnostic and therapeutic) MNP. Thus, these biogenic MNP particles offer a level of precision and versatility that synthetic methods cannot match.
However, purification of magnetosomes in high yield from native MTB poses challenges due to cumbersome cultivation and low productivity of these strains. One of the main achievements of earlier ERC-funded research in our AdG-project Syntomagx was the successful transplantation of the complex biosynthetic pathway for magnetosomes from native MTB to novel host microbial host organisms, among them several biotechnologically more amenable strains. Syntomagx has also laid the technological groundwork for the creation of designer MNP with customizable features, such as enzyme or antibody attachments.
The aim of the present project, BacToMagicle, was to unlock the commercial potential of high-quality magnetic nanoparticles from bioengineered, synthetically magnetized bacteria (SynBacMag) by testing scalability of their production and validating their performance and safety in clinical imaging applications like MPI.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We constructed a number of genetically engineered mutants of the model strain Magnetospirillum gryphiswaldense (Mgryph) capable of efficiently producing SynBacMag with defined and genetically controlled sizes. This included three strains producing superparamagnetic particles smaller than the model wildtype, by size range and magnetic properties ideally suited for magnetic particle imaging (MPI). In parallel, we optimized large-scale cultivation regimes for Mgryph, achieving robust growth of wild-type and engineered strains in volumes up to 10 liters. Significant progress was also made in downstream processing of SynBacMag-producing cells and particle purification. A thoroughly revised protocol addressing decrease of contamination with the outer membrane component lipid A led to drastic reduction of endotoxin levels in and immunogenic response to Mgryph particle preparations. Thus, we achieved an important goal for biomedical particle applications, since these results promise high biocompatibility of the SynBacMag isolated and purified from our engineered strains. The biogenic particles were evaluated for their performance in MPI in collaboration with our biomedical research partners. For MPI, a relatively recent radiation-free tomographic imaging method with superior temporal resolution, tracers with a magnetic core diameter of about 25-28 nm (superparamagnetic) and a single-domain magnetic moment are highly desirable. Excellent performance in phantom studies of a pre-clinical setting could be demonstrated for one of the genetically engineered Mgryph strains. This particle type outperformed commercially available standard tracers in MPI-phantom experiments. A comprehensive market analysis has been conducted, and intellectual property right options are evaluated with respect to exploitation of the project results in a potential spin-off company.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

In the present project, we took great steps towards a successful commercialization of biogenic magnetic nanoparticles for biomedical applications by engineering suitable bacterial strains for large-scale production of low-toxicity MNP with excellent performance as tracers in magnetic particle imaging. Their unique combination of quality, tunability, and biocompatibility position SynBacMag as a high-value product with strong potential for widespread clinical and commercial adoption.